A new trading day began on Friday, with Editas Medicine Inc (NASDAQ: EDIT) stock price up 4.32% from the previous day of trading, before settling in for the closing price of $1.39. EDIT’s price has ranged from $0.91 to $6.69 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 96.99%. Meanwhile, its annual earnings per share averaged 47.89%. With a float of $82.93 million, this company’s outstanding shares have now reached $83.71 million.
Let’s determine the extent of company efficiency that accounts for 246 employees. In terms of profitability, gross margin is 82.02%, operating margin of -777.25%, and the pretax margin is -733.74%.
Editas Medicine Inc (EDIT) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Editas Medicine Inc is 0.93%, while institutional ownership is 60.78%. The most recent insider transaction that took place on Mar 04 ’25, was worth 7,030. In this transaction EVP, CHIEF FINANCIAL OFFICER of this company sold 4,109 shares at a rate of $1.71, taking the stock ownership to the 112,720 shares. Before that another transaction happened on Mar 04 ’25, when Company’s CEO sold 16,632 for $1.71, making the entire transaction worth $28,452. This insider now owns 295,474 shares in total.
Editas Medicine Inc (EDIT) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 47.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.95% during the next five years compared to -1.48% drop over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Here are Editas Medicine Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.88, a number that is poised to hit -0.56 in the next quarter and is forecasted to reach -1.11 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Looking closely at Editas Medicine Inc (NASDAQ: EDIT), its last 5-days average volume was 1.82 million, which is a drop from its year-to-date volume of 3.27 million. As of the previous 9 days, the stock’s Stochastic %D was 21.28%. Additionally, its Average True Range was 0.15.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 22.60%, which indicates a significant decrease from 36.36% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 105.98% in the past 14 days, which was lower than the 162.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4147, while its 200-day Moving Average is $2.4260. However, in the short run, Editas Medicine Inc’s stock first resistance to watch stands at $1.5167. Second resistance stands at $1.5833. The third major resistance level sits at $1.6367. If the price goes on to break the first support level at $1.3967, it is likely to go to the next support level at $1.3433. Now, if the price goes above the second support level, the third support stands at $1.2767.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
With a market capitalization of 121.38 million, the company has a total of 83,710K Shares Outstanding. Currently, annual sales are 32,310 K while annual income is -237,090 K. The company’s previous quarter sales were 30,610 K while its latest quarter income was -45,390 K.
